NYSE:CLX

Clorox Company (CLX)

99.32
+0.84 (0.85%)
as of Jun 10, 2026, 8:00:00 pm Market Open.
76 watching
0
Investor Insights
star iconJun 9, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

The Clorox Company, listed under the symbol CLX-N, is facing mixed reviews from experts. While it boasts a solid dividend yield of around 4.9% to 5% and has maintained a history of increasing dividends for 24 years, its stock has experienced significant volatility, including a notable decline of over 30% in the current year. Analysts highlight the company's attractive valuation at 16x earnings compared to its historical range of 18-20x, indicating it might be trading at a discount. However, concerns about inflation affecting consumer willingness to pay for name brands could be a headwind moving forward. Additionally, fluctuations in oil prices impact the company's performance due to reliance on oil-based products, making it uniquely sensitive to global events.

consensus icon
Consensus
Negative
valuation icon
Valuation
Undervalued
review icon
Similar
PG, 'Procter & Gamble'
DON'T BUY
Wall Street is circumspect about it, considering it a stay at home stock. As a battleground stocks now, avoid.
TOP PICK
It has been around since 1913. They ran higher as the pandemic was getting under swing. They sold off because the spike in demand will decline as the pandemic goes away. He is not convinced demand will decline. People are more mindful now of germs and washing their hands. Most of their sales come from brands that are number 1 or 2. They have little or no debt. (Analysts’ price target is $213.47)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly CLX rose to to the forefront at the beginning of the pandemic with its sterile cleaning products. Now with the economy beginning to reopen, demand for its products are expected to remain strong. Margins continue to expand for the 9th consecutive period thanks to volume and cost-saving efficiencies. It pays a good dividend, that has been increasing for 40 consecutive years and is backed by a 45% payout ratio. We would buy this with a stop-loss at $150 looking to achieve $220 -- upside potential over 17%. Yield 2.34% (Analysts’ price target is $219.29)
WAIT
They just delivered 26% organic growth, but they won't meet demand for wipes until the end of the year. What happens to this stock when we return to normal? Will hygiene habits endure? Will demand still be there? He really doesn't know yet. Maybe they can still sell a lot of wipes, but it may not be enough to move the needle.
BUY
It reported today a massive 90-cent earnings beat, and the stock popped up more than 4%. He recommends this as part of the Hygiene Bull Market during Covid.
BUY
It has thrived during Covid which offers a range of cleaning products. This stock will do regardless of who wins the White House.
BUY
This is synonymous with lockdowns, but still fell 2% in today's big sell-off. Hygiene stocks will continue to see a bull run during this pandemic.
DON'T BUY
The rally has been played out, despite the current "hygiene" rally driven by Covid. Clorox owns a range of products outside hygiene. A mish mash.
DON'T BUY
He doesn't mind it and has owned it, but current levels are too high. There are better stocks elsewhere.
DON'T BUY
He is not a huge fan. It has always been an expensive place to park money. You pay a high premium for low growth. There is not a lot of room to grow in traditional product lines. Growth will be challenged for a year or so.
BUY

A very good company. It's one of the consumer product stocks that has actually had constant growth. They generate free cash flow. Dividend growth has been above average.

COMMENT

This is in the Consumer Products/Consumer Staples category, which he is more negative on. However, this has done better than the group. They recently produced a decent earnings number. Prefers other areas.

COMMENT

Their biggest problem is that it is in “consumer staples”, a sector that is very expensive. These companies have very little scope for growth. There was expensive premiumization on a lot of these companies and not in a position to trade down as people wanted less expensive products. There was also a lot of reliance on growth in emerging markets, which has decelerated very sharply.

COMMENT

This is a part of the whole consumers package goods business that is under incredible pressure from commoditization. The stock has done very, very well. It had high PEs just because of the quality of their cash flow and that their brand names are recognized. Now that we are getting into higher interest rates, that is going to start to get squeezed. Maybe the weakening of the US$ will allow some foreign profits to come through a little better, but generally the group is under a lot of pressure from generics, etc. If you own it, you are not going to lose a lot of money.

DON'T BUY

The Fair Market Value is 41% below the current price. It is currently trading at the Price to Book of 25X. This stock is simply not investment grade anymore.

Showing 16 to 30 of 35 entries